Give your patients long-term clarity and quality of vision by a new measure in toric stability. enVista Toric comes with unique haptics that are designed to secure a predictable astigmatism correction, hence providing long-term stable vision1.
enVista Toric Material and design resists growth of LECs into the optic and limit PCO1, thus providing a long-term optical clarity1.
enVista TORIC Intraocular lens
In Quest of Perfection, the New Measure in Toric Stability. enVista Toric has demonstrated excellent rotational stability1 in clinical studies
Incorporates Advanced Optics (AO) Technology for2:
- Reduced postoperative spherical aberration
- No image degradation with decentration
- Less sensitive to tilt
- Enhanced depth of field
DESIGNED TO SECURE A PREDICTABLE ASTIGMATISM CORRECTION AND MINIMIZE PCO
Haptics2
- Fenestrated and step-vaulted
- Contact angle of 56°
- Posterior vaulting
Optic
- Square posterior edge designed to optimize 360° capsular contact1,2
- Clear vision through aberration-free, aspheric optics3-5
Material
- No glistenings detected at any time in a 2-year prospective study of 172 eyes6
Advanced ease of use2
- Safe, simple, reliable insertion through a 2.2-mm incision with a single-use injector
- Precise positioning in the capsular bag and removal of viscoelastic are facilitated by controlled unfolding
|
Material
|
Hydrophobic Acrylic with UV Absorber
|
|
Refractive Index
|
1.54 at 35°C
|
|
Optic Size
|
6.0mm
|
|
Haptics
|
Modified C, Step-vaulted, Fenestrated Haptics
|
|
Optic Design
|
One-Piece, bi-convex aspheric optic Posterior toric surface
|
|
Overall Diameter
|
12.5mm
|
|
Sphere Powers Range
Cylinder Powers IOL Plane
Cylinder Powers Corneal Plane
|
+6.0 D to 30.0 D in 0.5-D increments
1.25 D, 2.00 D, 2.75 D, 3.50 D, 4.25 D, 5.00 D, 5.75 D
0.90 D, 1.40 D, 1.93 D, 2.45 D, 2.98 D, 3.50 D, 4.03 D
|
|
A-Constant*
|
US Biometry = 118.7
Optical Biometry = 119.1
|
|
ACD*
|
Applanation A-Scan = 5.37
Optical Biometry = 5.61
|
|
Surgeon Factor*
|
Applanation A-Scan = 1.62
Optical Biometry = 1.85
|
|
Product Order Code
|
MX60T (Lens)
INJ100 (single use Injector)
|
enVista® TORIC Intraocular lens : Additional information |
References:
1. Packer M et al. Prospective multicenter clinical trial to evaluate the safety and effectiveness of a new glistening-free one-piece acrylic toric intraocular lens. Clinical Ophthalmology 2018:12 1031. 2. Data on file Bausch & Lomb Incorporated. 3. Santhiago MR, Netto MV, Barreto J Jr, et al. Wavefront analysis, contrast sensitivity, and depth of focus after cataract surgery with aspherical intraocular lens implantation. Am J Ophthalmol. 2010;149(3):383-389. 4. Pepose JS, Qazi MA, Edwards KH, Sanderson JP, Sarver EJ. Comparison of contrast sensitivity, depth of field and ocular wavefront aberrations in eyes with an IOL with zero versus positive spherical aberration. Graefe’s Arch Clin Exp Ophthalmol. 2009;247(7):965-973. 5. Johansson B, Sundelin S, Wikberg-Matsson A, Unsbo P, Behndig A. Visual and optical performance of the Akreos® Adapt Advanced Optics and Tecnis Z9000 intraocular lenses: Swedish multicenter study. J Cataract Refract Surg. 2007;33(9):1565-1572 6. enVista® Directions for Use.
INDICATIONS: Indicated for primary implantation for the visual correction of aphakia in adult patients with pre-existing corneal astigmatism in whom the cataractous lens has been removed. The lens is intended for placement in the capsular bag.
WARNINGS: Physicians considering lens implantation under any of the following circumstances should weigh the potential risk/benefit ratio: 1. Recurrent severe anterior or posterior segment inflammation or uveitis. 2. Patients in whom the intraocular lens may affect the ability to observe, diagnose, or treat posterior segment diseases. 3. Surgical difficulties at the time of cataract extraction, which might increase the potential for complications (e.g. persistent bleeding, significant iris damage, uncontrolled positive pressure, or significant vitreous prolapse or loss). 4. A distorted eye due to previous trauma or developmental defect in which appropriate support of the IOL is not possible. 5. Circumstances that would result in damage to the endothelium during implantation. 6. Suspected microbial infection. 7. Children under the age of 2 years are not suitable candidates for intraocular lenses. 8. Patients in whom neither the posterior capsule nor zonules are intact enough to provide support.
PRECAUTIONS: Do not attempt to re-sterilize the lens as this can produce undesirable side effects. Do not soak or rinse the intraocular lens with any solution other than sterile balanced salt solution or sterile normal saline. Do not store the lens at a temperature greater than 43°C (110°F). DO NOT FREEZE. Do not autoclave the intraocular lens. Do not reuse the lens. It is intended for permanent implantation. If explanted, sterility and proper function cannot be assured. For complete physician labeling information, refer to the enVista™ Toric product package insert.
*A-constant, ACD and Surgeon Factor are estimates only. It is recommended that each surgeon develop his/her own values.